Cevec Pharmaceuticals, a Germany-based developer of biopharmaceuticals and vaccines, has raised €2.8m ($4m) in its series C round from a consortium including local pharmaceutical distributor Midas Group. Venture capital firm Peppermint Venture Partners led the C round using money from the €31m Charité Biomedical Fund investing on behalf of the Germany-based medical training university Charité…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
